Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK2 | O96017 | 5/20 | 0.58 |
| ▸ | SMAD3 | P84022 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.46 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | CASR | P41180 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL183922 | 1.00 | CHEK2 (0.58) | CHEK2SMAD3KMT2AMEN1ALDH1A1 | |
| SCHEMBL1621893 | 0.94 | SMAD3 (0.56) | CHEK2SMAD3KMT2AMEN1ALDH1A1 | |
| SCHEMBL13769449 | 0.88 | CHEK2 (0.62) | CHEK2SMAD3KMT2AMEN1ALDH1A1 | |
| SCHEMBL1623570 | 0.87 | CHEK2 (0.55) | CHEK2SMAD3KMT2AMEN1ALDH1A1 | |
| SCHEMBL1623569 | 0.87 | CHEK2 (0.55) | CHEK2SMAD3KMT2AMEN1ALDH1A1 | |
| SCHEMBL1084343 | 0.86 | CHEK2 (0.56) | CHEK2SMAD3KMT2AMEN1ALDH1A1 | |
| SCHEMBL1084638 | 0.86 | CHEK2 (0.56) | CHEK2SMAD3KMT2AMEN1ALDH1A1 | |
| SCHEMBL1084832 | 0.85 | CHEK2 (0.80) | CHEK2SMAD3KMT2AMEN1ALDH1A1 | |
| SCHEMBL1084555 | 0.85 | CHEK2 (0.80) | CHEK2SMAD3KMT2AMEN1ALDH1A1 | |
| SCHEMBL1084749 | 0.84 | CHEK2 (0.57) | CHEK2SMAD3KMT2AMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8809353-B2 | Quinazolines useful as modulators of voltage gated ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-19 | — | — | US | disclosed |
| US-8283354-B2 | Voltage gated sodium and calcium channel inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-10-09 | — | — | US | disclosed |
| US-8158637-B2 | Sodium channel moderators; antiarrhythmia agents; analgesics; antiarthritic agents; antiinflammatory agents; antieplipetic agents; psychological disorders; nervous system disorders | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-04-17 | — | — | US | disclosed |
| EP-1957482-B1 | QUINAZOLINES USEFUL AS MODULATORS OF VOLTAGE GATED ION CHANNELS | VERTEX PHARMA (US) | 2012-01-04 | — | — | EP | disclosed |
| US-7928107-B2 | Quinazolines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-04-19 | — | — | US | disclosed |
| US-20090312342-A1 | Quinazolines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2009-12-17 | — | — | US | disclosed |
| EP-1784393-B1 | QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS | VERTEX PHARMA (US) | 2009-07-01 | — | — | EP | disclosed |
| US-20080221137-A1 | Quinazolines useful as modulators of voltage gated ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2008-09-11 | — | — | US | disclosed |
| EP-1957482-A2 | QUINAZOLINES USEFUL AS MODULATORS OF VOLTAGE GATED ION CHANNELS | Vertex Pharmaceuticals, Inc. (US) | 2008-08-20 | — | — | EP | disclosed |
| US-20080167305-A1 | QUINAZOLINES USEFUL AS MODULATORS OF VOLTAGE GATED ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2008-07-10 | — | — | US | disclosed |
| WO-2007058989-A2 | QUINAZOLINES USEFUL AS MODULATORS OF VOLTAGE GATED ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-05-24 | — | — | WO | disclosed |
| US-20060173018-A1 | Quinazolines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2006-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312342-A1 | Quinazolines useful as modulators of ion channels | KCNQ1, KCNQ2, KCNN3 | CHEK2 2935/4885SMAD3 4194/4885KMT2A 2404/4885 |
| US-20060173018-A1 | Quinazolines useful as modulators of ion channels | KCNQ1, KCNQ2, KCNN3 | CHEK2 2935/4885SMAD3 4194/4885KMT2A 2404/4885 |
| US-20080167305-A1 | QUINAZOLINES USEFUL AS MODULATORS OF VOLTAGE GATED ION CHANNELS | KCNQ1, KCNQ2, KCNQ5 | CHEK2 3091/4885SMAD3 4191/4885KMT2A 2233/4885 |
| US-20080221137-A1 | Quinazolines useful as modulators of voltage gated ion channels | KCNQ1, KCNQ2, KCNQ5 | CHEK2 3091/4885SMAD3 4191/4885KMT2A 2233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.